18 known cases. View patent page →
Jazz sued Roxane Laboratories (later Hikma/West-Ward) asserting the '650 patent. The case was consolidated with 2:10-cv-06108 and 2:12-cv-07459 in April 2013, and the consolidated case settled April 5, 2017, granting Hikma/West-Ward an authorized generic of Xyrem beginning Jan. 1, 2023.
Filed after Amneal's Dec. 10, 2012 Paragraph IV notice. Amneal counterclaimed for non-infringement/invalidity of the '650 patent, inequitable conduct, and prosecution laches; the case settled.
Filed after Par's Nov. 20, 2013 Paragraph IV notice; settled.
Filed after Ranbaxy's June 3, 2014 Paragraph IV notice; settled. The narrative lists this docket and/or 2:14-cv-04467 for the Ranbaxy suit.
Filed after Watson's Oct. 29, 2014 Paragraph IV notice regarding ANDA No. 204952 (500 mg/mL sodium oxybate). The complaint names the '650 patent as a patent-in-suit; settled.
Filed after Wockhardt's June 8, 2015 Paragraph IV notice; settled.
Filed after Lupin's July 23, 2015 Paragraph IV notice. The complaint confirms the '650 patent as a patent-in-suit; settled.
Filed after Ascent's June 14, 2017 Paragraph IV notice regarding ANDA No. 210523 (500 mg/mL sodium oxybate). The complaint names the '650 patent; settled per overall narrative.
Party name not retrieved; listed as Xyrem-family litigation.
Terminated June 15, 2018.
MDL antitrust litigation in which the '650 patent is identified in complaints as one of the Xyrem patents central to the alleged evergreening/sham-litigation scheme. Final settlement approval order entered Oct. 27, 2025.
Antitrust action by New York State Teamsters Council Health & Hospital Fund against Jazz, with Roxane named as a party; consolidated into/related to the Xyrem MDL.
Antitrust action terminated July 15, 2020, likely transferred to the Xyrem MDL.
Blue Cross affiliate/related antitrust action terminated July 14, 2020.
Indirect purchaser class action by Hollman against Jazz; consolidated into/related to the Xyrem MDL.
Class action related to the Xyrem MDL.
Antitrust action terminated April 15, 2021, likely transferred to the Xyrem MDL.
Jazz Pharmaceuticals sued Ranbaxy Laboratories and Ranbaxy Inc. in a Hatch-Waxman ANDA patent infringement action over generic sodium oxybate referencing Xyrem. The complaint asserted multiple patents including U.S. Patent No. 8,461,203. The case was consolidated for all purposes into Jazz Pharmaceuticals, Inc. v. Amneal Pharmaceuticals, LLC, No. 13-391-ES-JAD, and administratively terminated.